Pertuzumab: Unprecedented benefit in human epidermal growth factor receptor 2-positive breast cancer
Human epidermal growth factor receptor 2 (HER2)-positive breast cancer is a more aggressive subtype of breast cancer and targeting the HER2 receptor has proven effective in improving the prognosis of these patients. Pertuzumab, a recombinant humanized monoclonal antibody and the first in a class of...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Thieme Medical Publishers, Inc.
2015-07-01
|
| Series: | Asian Journal of Oncology |
| Subjects: | |
| Online Access: | http://www.thieme-connect.de/DOI/DOI?10.4103/2454-6798.173299 |
| _version_ | 1818190351872032768 |
|---|---|
| author | Amit Rauthan Palanki Satya Dattatreya Manish Singhal Ram Prabu Siddharth Naik Anil Kukreja |
| author_facet | Amit Rauthan Palanki Satya Dattatreya Manish Singhal Ram Prabu Siddharth Naik Anil Kukreja |
| author_sort | Amit Rauthan |
| collection | DOAJ |
| description | Human epidermal growth factor receptor 2 (HER2)-positive breast cancer is a more aggressive subtype of breast cancer and targeting the HER2 receptor has proven effective in improving the prognosis of these patients. Pertuzumab, a recombinant humanized monoclonal antibody and the first in a class of HER2 dimerization inhibitors approved for treating HER2+ breast cancer. It blocks ligand-dependent heterodimerization and ligand-independent homodimerization of HER2 with other HER members. When used in combination with trastuzumab and taxane, pertuzumab complements the action of trastuzumab and results in a comprehensive blockade of HER2 signaling pathway. This review article traces the development of pertuzumab from concept to its current use in HER2+ breast cancer treatment. A search of Medical Literature Published since 2007 was performed in PubMed using the keywords “pertuzumab,” “HER2+ breast cancer,” “HER2 targeted therapy,” “metastatic breast cancer,” and in search engines for ongoing trials with pertuzumab and incidence of cancer and breast cancer in India. A total of 35 publications and abstracts from the American Society of Clinical Oncology were selected for this review. Pertuzumab is approved in combination with trastuzumab and docetaxel for the treatment of patients with HER2+ metastatic BC, who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease. The dual HER2 blockade of pertuzumab and trastuzumab is now accepted worldwide as a standard of care by various guidelines. |
| first_indexed | 2024-12-11T23:57:20Z |
| format | Article |
| id | doaj.art-c127dfe7c98d4ecbbcd122a4252693d7 |
| institution | Directory Open Access Journal |
| issn | 2454-6798 2455-4618 |
| language | English |
| last_indexed | 2024-12-11T23:57:20Z |
| publishDate | 2015-07-01 |
| publisher | Thieme Medical Publishers, Inc. |
| record_format | Article |
| series | Asian Journal of Oncology |
| spelling | doaj.art-c127dfe7c98d4ecbbcd122a4252693d72022-12-22T00:45:19ZengThieme Medical Publishers, Inc.Asian Journal of Oncology2454-67982455-46182015-07-01010208409110.4103/2454-6798.173299Pertuzumab: Unprecedented benefit in human epidermal growth factor receptor 2-positive breast cancerAmit Rauthan0Palanki Satya Dattatreya1Manish Singhal2Ram Prabu3Siddharth Naik4Anil Kukreja5Department of Oncology, Manipal Hospitals, Bengaluru, Karnataka, IndiaDepartment of Medical Oncology, Omega Hospitals, Hyderabad, Telangana, IndiaInstitutes of Cancer, Indraprastha Apollo Hospital, New Delhi, IndiaMIOT Institute of Cancer Cure, MIOT Hospitals, Chennai, Tamil Nadu, IndiaDepartment of Medical Affaire, Roche Products (India) Pvt. Ltd., Mumbai, Maharashtra, IndiaDepartment of Medical Affaire, Roche Products (India) Pvt. Ltd., Mumbai, Maharashtra, IndiaHuman epidermal growth factor receptor 2 (HER2)-positive breast cancer is a more aggressive subtype of breast cancer and targeting the HER2 receptor has proven effective in improving the prognosis of these patients. Pertuzumab, a recombinant humanized monoclonal antibody and the first in a class of HER2 dimerization inhibitors approved for treating HER2+ breast cancer. It blocks ligand-dependent heterodimerization and ligand-independent homodimerization of HER2 with other HER members. When used in combination with trastuzumab and taxane, pertuzumab complements the action of trastuzumab and results in a comprehensive blockade of HER2 signaling pathway. This review article traces the development of pertuzumab from concept to its current use in HER2+ breast cancer treatment. A search of Medical Literature Published since 2007 was performed in PubMed using the keywords “pertuzumab,” “HER2+ breast cancer,” “HER2 targeted therapy,” “metastatic breast cancer,” and in search engines for ongoing trials with pertuzumab and incidence of cancer and breast cancer in India. A total of 35 publications and abstracts from the American Society of Clinical Oncology were selected for this review. Pertuzumab is approved in combination with trastuzumab and docetaxel for the treatment of patients with HER2+ metastatic BC, who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease. The dual HER2 blockade of pertuzumab and trastuzumab is now accepted worldwide as a standard of care by various guidelines.http://www.thieme-connect.de/DOI/DOI?10.4103/2454-6798.173299breast cancerhuman epidermal growth factor receptor 2pertuzumab |
| spellingShingle | Amit Rauthan Palanki Satya Dattatreya Manish Singhal Ram Prabu Siddharth Naik Anil Kukreja Pertuzumab: Unprecedented benefit in human epidermal growth factor receptor 2-positive breast cancer Asian Journal of Oncology breast cancer human epidermal growth factor receptor 2 pertuzumab |
| title | Pertuzumab: Unprecedented benefit in human epidermal growth factor receptor 2-positive breast cancer |
| title_full | Pertuzumab: Unprecedented benefit in human epidermal growth factor receptor 2-positive breast cancer |
| title_fullStr | Pertuzumab: Unprecedented benefit in human epidermal growth factor receptor 2-positive breast cancer |
| title_full_unstemmed | Pertuzumab: Unprecedented benefit in human epidermal growth factor receptor 2-positive breast cancer |
| title_short | Pertuzumab: Unprecedented benefit in human epidermal growth factor receptor 2-positive breast cancer |
| title_sort | pertuzumab unprecedented benefit in human epidermal growth factor receptor 2 positive breast cancer |
| topic | breast cancer human epidermal growth factor receptor 2 pertuzumab |
| url | http://www.thieme-connect.de/DOI/DOI?10.4103/2454-6798.173299 |
| work_keys_str_mv | AT amitrauthan pertuzumabunprecedentedbenefitinhumanepidermalgrowthfactorreceptor2positivebreastcancer AT palankisatyadattatreya pertuzumabunprecedentedbenefitinhumanepidermalgrowthfactorreceptor2positivebreastcancer AT manishsinghal pertuzumabunprecedentedbenefitinhumanepidermalgrowthfactorreceptor2positivebreastcancer AT ramprabu pertuzumabunprecedentedbenefitinhumanepidermalgrowthfactorreceptor2positivebreastcancer AT siddharthnaik pertuzumabunprecedentedbenefitinhumanepidermalgrowthfactorreceptor2positivebreastcancer AT anilkukreja pertuzumabunprecedentedbenefitinhumanepidermalgrowthfactorreceptor2positivebreastcancer |